ARCHIVES

FDA To Once Again Review ESA Label To Reflect Results Of Negative Studies.

This article is from The Cancer Letter archive.

Vol. 33 No. 45 | December 7, 2007

Download PDF Visit The Full Archive

Related Articles

ASCO 2012: Michael Link’s Presidential Address, and the 2012 Award Winners

June 8, 2012

ODAC Okays First “Paper NDA,” By BMS For Bieomycin

October 1, 1993

Iressa Shrinks Some Lung Tumors, Reduces Symptoms In Phase II Trial

June 28, 2002

Neutron Therapy Contracts Wind Down Next Year; DCT To Consider Whether To Continue Support

March 25, 1988

NCI Developing Policy On Relations Between Industry, DCT Clinical Trials

July 29, 1983

SWOG Phase III Trial To Test Treatment For Inoperable, Locally Advanced NSCLC

September 28, 2001